ライフサイエンスコーパス: thrombocytosis

1 sed cancer often have a high platelet count (thrombocytosis).

2 itor cells, megakaryocyte ploidy status, and thrombocytosis.

3 eletion syndrome characterized by anemia and thrombocytosis.

4 ion seen in 5q- syndrome, it does not affect thrombocytosis.

5 es that are somatically mutated in essential thrombocytosis.

6 marrow and are reflected by neutrophilia and thrombocytosis.

7 der, that is, polycythemia vera or essential thrombocytosis.

8 e diagnosis of ET associated with borderline thrombocytosis.

9 in JAK2-negative myelofibrosis and essential thrombocytosis.

10 topoiesis, and bone marrow fibrosis, but not thrombocytosis.

11 tent progenitors, aberrant lymphopoiesis and thrombocytosis.

12 xpression of Mpl and a clinical phenotype of thrombocytosis.

13 changes, edema, sclerotic bone lesions, and thrombocytosis.

14 and in the other in the setting of essential thrombocytosis.

15 ng paquinimod), all reduced diabetes-induced thrombocytosis.

16 ant feature was the development of a chronic thrombocytosis.

17 consensus exists regarding the treatment of thrombocytosis.

18 ncy, thymic hypoplasia, megakaryocytosis and thrombocytosis.

19 guish between primary and secondary forms of thrombocytosis.

20 35.4%) were the primary agents used to treat thrombocytosis.

21 sive organomegaly, leukocytosis, anemia, and thrombocytosis.

22 muscle contractility, low blood pressure and thrombocytosis.

23 cytokine that is implicated in inflammatory thrombocytosis.

24 th treatment response and thrombotic risk in thrombocytosis.

25 associated with thrombotic complications in thrombocytosis.

26 ss thrombosis risk and treatment response in thrombocytosis.

27 y did not have pretreatment splenomegaly and thrombocytosis.

28 yeloproliferative disorders versus secondary thrombocytosis.

29 R) and who had pretreatment splenomegaly and thrombocytosis.

30 erentially expanded in CALR mutant mice with thrombocytosis.

31 were observed, except for 1 case of neonatal thrombocytosis.

32 nt cancers within 5 years after diagnosis of thrombocytosis.

33 ebrand disease, which can occur with extreme thrombocytosis.

34 and proliferation, resulting in reticulated thrombocytosis.

35 ation in JAK2V617I-positive individuals with thrombocytosis.

36 rrow compartment and the VEGF-A(165)-induced thrombocytosis.

37 as an underlying mechanism of paraneoplastic thrombocytosis.

38 the underlying mechanisms of paraneoplastic thrombocytosis.

39 iesis, resulting in lymphopenia, anemia, and thrombocytosis.

40 2-V617F-mediated polycythemia vera/essential thrombocytosis.

41 ocytopenia (one [0.3%] vs three [5.6%]), and thrombocytosis (0 vs four [7.5%]).

42 by erythrocytosis and often leukocytosis and thrombocytosis(1).

43 rrow trephine specimens of 183 patients with thrombocytosis-164 with essential thrombocythemia (ET),

44 brosis, but not in 4 patients with essential thrombocytosis, 3 with chronic myelogenous leukemia, 6 w

45 patients; musculoskeletal pain, 5 patients; thrombocytosis, 4 patients; edema, 3 patients; diarrhea

46 ion in 83 patients with chronic or transient thrombocytosis, 46 patients with deep vein (DVT) or arte

47 is a required diagnostic criterion, although thrombocytosis (53%) and leukocytosis (49%) are common.

48 wn function, into Ldlr(-/-) mice resulted in thrombocytosis, accelerated thrombosis and atheroscleros

49 bone marrow that are causative for an acute thrombocytosis accompanied by anemia.

50 ozygous CALR(del/del) mice developed extreme thrombocytosis accompanied by features of MF, including

51 In addition to the expected thrombocytosis after 7 to 10 days of daily injection of

52 has highlighted a high frequency of extreme thrombocytosis after TPIAT, but its cause and associatio

53 d routine CBC test result, 53 339 (1.6%) had thrombocytosis and a prior normal platelet count.

54 ody effectively prevented the development of thrombocytosis and accumulation of megakaryocytes in the

55 cyte commitment, which ultimately results in thrombocytosis and anemia.

56 Associations were found between thrombocytosis and cancers of the ovary (RR, 7.11; 95% C

57 inhibition may represent a new treatment for thrombocytosis and clotting disorders.

58 zing expression patterns in 79 subjects with thrombocytosis and controls, and integrated data with tr

59 s of co-existing platelets cause age-related thrombocytosis and dramatically increased thrombosis in

60 karyocytopoiesis and myelopoiesis leading to thrombocytosis and granulocytosis.

61 K2V617I mutation in a family with hereditary thrombocytosis and herein characterize the hematopoietic

62 patients at low risk, definition of extreme thrombocytosis and its management in patients at low ris

63 elated symptoms and splenomegaly, concurrent thrombocytosis and leukocytosis, or intolerance of phleb

64 ve disorder in JAK2 and MPL wt patients with thrombocytosis and may have prognostic and therapeutic r

65 th acquired iron deficiency anemia also show thrombocytosis and Mk-biased MEPs.

66 n approximately half of those with essential thrombocytosis and myelofibrosis.

67 5, tgif1, irf8, cebpa, and rorca that showed thrombocytosis and one gene, ikzf1 that showed thrombocy

68 Thrombocytosis and platelet hyperreactivity are known to

69 These results suggest that post-TPIAT thrombocytosis and portal vein thromboses may be linked

70 Consequently, CD24 blockade improves thrombocytosis and prevents myelofibrosis in MPN mice.

71 V shares the same JAK2 mutation as essential thrombocytosis and primary myelofibrosis, but erythrocyt

72 between PMF and polycythemia vera/essential thrombocytosis and reveal methylomic signatures of ASXL1

73 orate the course of MPN, but rather enhanced thrombocytosis and shortened the overall survival.

74 t and haemoglobin electrophoresis to exclude thrombocytosis and sickle cell anaemia, and serum angiot

75 a define a dysregulated miRNA fingerprint in thrombocytosis and support a developmentally restricted

76 s were associated with polyclonal hereditary thrombocytosis and triple-negative MPNs.

77 ith Down syndrome (DS) display macrocytosis, thrombocytosis, and a 500-fold increased risk of develop

78 CMV/IL-33 mice also suffer from anemia, thrombocytosis, and a marked dysregulation of myelopoies

79 K2 mutations in polycythemia vera, essential thrombocytosis, and chronic idiopathic myelofibrosis.

80 in inflammation (reduction in leukocytosis, thrombocytosis, and circulating interleukin-6 levels), r

81 21-miRNA genetic fingerprint associated with thrombocytosis, and demonstrated that a 3-member subset

82 notable for profound iron deficiency anemia, thrombocytosis, and hyperhomocysteinemia.

83 le, ring sideroblasts associated with marked thrombocytosis, and juvenile myelomonocytic leukemia, ar

84 Antibiotic-treated mice exhibited anemia, thrombocytosis, and leukopenia, with pronounced pan-lymp

85 asms, including polycythemia vera, essential thrombocytosis, and myelofibrosis, are disorders charact

86 methylation in polycythemia vera, essential thrombocytosis, and PMF samples compared with healthy co

87 ative disorders polycythemia vera, essential thrombocytosis, and primary myelofibrosis are clonal dis

88 did not compromise PLT formation but caused thrombocytosis, and resulted in expansion of MK progenit

89 ypoplasia, and megakaryocytic dysplasia with thrombocytosis, and that p53 plays a critical role in ma

90 oiesis seen in patients who develop reactive thrombocytosis, and these cytokines also are known to re

91 ing in hepatic fibrosis, transient postnatal thrombocytosis, anemia, a gene expression profile that i

92 c-Myc(-/-) mice develop a syndrome of severe thrombocytosis-anemia-leukopenia because of significant

93 The IL-6-dependent colitis-induced thrombocytosis appears to result from an enhancement of

94 ermined that polycythemia vera and essential thrombocytosis are characterized by aberrant promoter hy

95 teria for distinguishing among etiologies of thrombocytosis are limited in their capacity to delineat

96 e significantly elevated in patients who had thrombocytosis as compared with those who did not.

97 < or = PHR and pretreatment splenomegaly or thrombocytosis at 3 months had such a low major cytogene

98 he majority of patients with leukocytosis or thrombocytosis at baseline (n = 28 and n = 10, respectiv

99 s had a nadir at day 3 followed by a rebound thrombocytosis at day 21, with nadir values significantl

100 Thrombocytosis, bone marrow megakaryocytic proliferation

101 Transgene rescued mice exhibit thrombocytosis but only partial correction of the stem c

102 egulation or inflammation signs (leukopenia, thrombocytosis, C-reactive protein, and erythrocyte sedi

103 In a mouse model of thrombocytosis (Calr(+/-)), there was a sustained increa

104 ase, manifesting either as erythrocytosis or thrombocytosis, can be initiated clonally from a single

105 stinct genetic biomarker subsets can predict thrombocytosis class using routine phlebotomy.

106 atelet transcriptome sequencing and extended thrombocytosis cohort analyses identified a single loss-

107 loped to assign phenotypic class between the thrombocytosis cohorts, and by JAK2 genotype.

108 unts revealed a profound reticulocytosis and thrombocytosis despite normal serum Epo levels and blood

109 -risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as ris

110 a lesser extent, CALRins5 (type II) induced thrombocytosis due to a megakaryocyte (MK) hyperplasia.

111 We speculate that countering paraneoplastic thrombocytosis either directly or indirectly by targetin

112 rmocytic normochromic anaemia, leucocytosis, thrombocytosis, elevated ESR (87 mm/hr), CRP (156 mg/L),

113 Laboratory tests were normal except thrombocytosis, elevated ESR, liver enzymes and ACE leve

114 lar volume overload, sclerotic bone lesions, thrombocytosis, elevated VEGF, and abnormal pulmonary fu

115 the MPN polycythemia vera (PV) and essential thrombocytosis (ET) by disrupting JAK2 protein stability

116 diopathic myelofibrosis (IMF), and essential thrombocytosis (ET).

117 as to define the contribution of IL-6 to the thrombocytosis, exaggerated agonist-induced platelet agg

118 this inflammation may reduce thrombosis and thrombocytosis frequencies simultaneously.

119 > or = 5 cm below the costal margin (BCM) or thrombocytosis > or = 700 x 10(9)/L pretreatment added s

120 e count is >10 x 10(9) cells per L), extreme thrombocytosis (>1500 x 10(9) platelets per L), inadequa

121 dy mass index (BMI; >/=25 kg/m(2)), ascites, thrombocytosis (>400,000 cells/mm(3)), albumin (<3.0 g/d

122 V617F transgenic mice with thrombocytosis had higher serum levels of IFNgamma than

123 Ovarian cancer patients with thrombocytosis had higher tumor proliferation indices co

124 ll 19 patients with familial polycythemia or thrombocytosis had polyclonal hematopoiesis, whereas 22

125 dic thrombocythemia (ST), 16 with hereditary thrombocytosis (HT), 11 with sporadic polycythemia (SP),

126 NF-E2 function and cause erythrocytosis and thrombocytosis in a murine model.

127 logist for evaluation of persistent isolated thrombocytosis in March 2012.

128 The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that plate

129 The mechanisms underlying thrombocytosis in patients with iron deficiency anemia r

130 sponsible for the well-documented finding of thrombocytosis in patients with iron deficiency anemia.

131 d hepatic thrombopoietin were also linked to thrombocytosis in patients.

132 g thrombopoietin and interleukin-6 abrogated thrombocytosis in tumor-bearing mice.

133 was essential for the CALR mutants to induce thrombocytosis in vivo, although Tpo contributes to dise

134 f these serious adverse events, headache and thrombocytosis, in one (2%) of 42 patients in the romipl

135 Among the 51 624 individuals with thrombocytosis included in the matched analysis, 2844 (5

136 The mechanisms behind the hereditary thrombocytosis induced by the thrombopoietin (THPO) rece

137 AP1 in cancer cells in vivo protects against thrombocytosis-induced increase in metastasis.

138 Infection-induced thrombocytosis is a clinically important complication of

139 Thrombocytosis is a common complication of rheumatoid ar

140 of essential thrombocythemia and hereditary thrombocytosis is acquired, and germ-line-activating mut

141 Thrombocytosis is an unexpected consequence of reduced M

142 Relative thrombocytosis is associated with a worse MICS profile,

143 Thrombocytosis is associated with inflammation, and cert

144 Paraneoplastic thrombocytosis is associated with many solid tumors and

145 Whether thrombocytosis is associated with the presence of an und

146 Thrombocytosis is often observed in gastrointestinal, lu

147 What initiates this reactive thrombocytosis is poorly understood.

148 Thrombocytosis is present in more than 30% of patients w

149 n to their role in rheumatoid arthritis with thrombocytosis, it has been demonstrated recently that m

150 ice exhibit many features of MPNs, including thrombocytosis, leukocytosis, Epo-independent colony for

151 D-dimer, and fibrinogen levels; tachycardia; thrombocytosis; leukocytosis; fever; leg edema; lower Ba

152 iculocytosis, leukocytosis, neutrophilia and thrombocytosis, marked expansion of erythroid progenitor

153 n = 71), MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T; n = 71), and MDS/MPN uncla

154 n JAK2V617F mice, decreasing erythrocytosis, thrombocytosis, megakaryocyte hyperplasia, and expansion

155 tive disease (MPD) characterized by profound thrombocytosis, megakaryocyte hyperplasia, dysplastic me

156 s of the c-Myb(M303V/M303V) mutation include thrombocytosis, megakaryocytosis, anemia, lymphopenia, a

157 leukocytes), and aberrant expression during thrombocytosis, most profound in ET.

158 current smoking, Killip class >/=2, baseline thrombocytosis, multivessel disease, symptom onset-to-ba

159 eveloped a significant MPN, characterized by thrombocytosis, neutrophilia, and splenomegaly.

160 edefined factors in the IMDC model (anaemia, thrombocytosis, neutrophilia, Karnofsky performance stat

161 stantial enlargement of the liver and marked thrombocytosis occurred in 16.1% and 22.0% of the patien

162 Eighty-two percent of physicians treated thrombocytosis only when platelet counts exceeded 1000 x

163 as a markedly worse prognosis than essential thrombocytosis or polycythemia vera, the molecular disti

164 ly as isolated erythrocytosis, leukocytosis, thrombocytosis, or any combination of these together wit

165 ts presence excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other cause

166 ited reciprocal reductions during periods of thrombocytosis (P < .07).

167 Decreased DLCO was associated with thrombocytosis (p = 0.05), with hepatic dysfunction (ele

168 absolute RP counts than asymptomatic chronic thrombocytosis patients (98 +/- 64 x 10(9)/L [range, 54

169 0.1%, mean +/- SD) than asymptomatic chronic thrombocytosis patients (n = 23, RP% = 3.4% +/- 1.8%), h

170 y) when compared with asymptomatic transient thrombocytosis patients (n = 40, 4.5% +/- 2.7% and 35 +/

171 Chronic thrombocytosis patients presenting with thrombosis (n =

172 Follow-up studies in seven chronic thrombocytosis patients showed that successful aspirin t

173 bsolute RP counts compared with only 1 of 63 thrombocytosis patients who remained asymptomatic.

174 In addition, 7 of 8 thrombocytosis patients who were studied before developi

175 absolute counts were also noted in transient thrombocytosis patients with thrombosis (n = 6, 11.5% +/

176 Chronic thrombocytosis patients with thrombosis also had signifi

177 nts remained significantly higher in chronic thrombocytosis patients with thrombosis when patients we

178 Of 409 patients, 67% developed extreme thrombocytosis, peaking around postoperative day 16.

179 Here, we report that the thrombocytosis phenotype induced by MPL P106L belongs to

180 d in Mpl(-/-) mice, MPL P106L could induce a thrombocytosis phenotype with high circulating THPO leve

181 nt; cytoreduction is recommended for extreme thrombocytosis (platelet count >1500 x 10(9) platelets p

182 ypothesized that ESRD patients with relative thrombocytosis (platelet count >300 x 10(3)/muL) have a

183 ese findings indicate that IL-6 mediates the thrombocytosis, platelet hyperreactivity, and accelerate

184 ractions between tumor growth/metastasis and thrombocytosis/platelet activation.

185 yeloproliferative neoplasms (MPNs) essential thrombocytosis, polycythemia vera, and primary myelofibr

186 ssic myeloproliferative neoplasms--essential thrombocytosis, polycythemia vera, and primary myelofibr

187 e have identified 2 families with hereditary thrombocytosis presenting novel heterozygous germ-line m

188 sideroblasts (RARS) and RARS associated with thrombocytosis (RARS-T), 2 distinct subtypes of MDS and

189 fractory anemia with ringed sideroblasts and thrombocytosis (RARS-T).

190 Thrombocytosis remains a marker of poor prognosis in pat

191 milial forms of nonclonal erythrocytosis and thrombocytosis, respectively.

192 The thrombocytosis response was absent in IL-6(-/-) mice.

193 PF4iCre;JAK2V617F/WT mice developed an early thrombocytosis resulting from the expression of JAK2V617

194 ent mice develop excess megakaryopoiesis and thrombocytosis revealing a novel mechanism of negative r

195 and adult patients analyzed the frequency of thrombocytosis, risk factors for thrombosis, and antipla

196 ntial thrombocythemia (ET), 19 with reactive thrombocytosis (RT)-for bone marrow angiogenesis, bone m

197 rombocythemia [ET]) from nonclonal (reactive thrombocytosis [RT]) etiologies.

198 s miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome.

199 ts suggest that individuals with unexplained thrombocytosis should be offered screening for several c

200 it, increased red blood cells, leukocytosis, thrombocytosis, splenomegaly, reduced serum erythropoiet

201 icantly and modulated 5-fluorouracil-induced thrombocytosis strongly, suggesting a regulatory role fo

202 loss, and rheumatoid arthritis patients with thrombocytosis tend to have more severe disease.

203 tients with type 2 diabetes have reticulated thrombocytosis that correlates with glycated hemoglobin

204 e a germline mutation that leads to familial thrombocytosis that involves a residue other than Val617

205 s that in rheumatoid arthritis with reactive thrombocytosis, the ability of the cytokines to enhance

206 Among individuals with thrombocytosis, the median age was 59.7 years (interquar

207 Celiac disease may also be associated with thrombocytosis, thrombocytopenia, leukopenia, venous thr

208 Thus, CALR mutants are sufficient to induce thrombocytosis through MPL activation.

209 Similarly, in MDS/MPN with thrombocytosis, transplantation is recommended on the ba

210 Treatment of reactive thrombocytosis using aspirin in adults and hydroxyurea i

211 an often indolent course, and (in essential thrombocytosis) usually a normal life span.

212 The thrombocytosis was associated with an increased risk of

213 However, the thrombocytosis was less sustained after single versus da

214 ained in JAK2V617F(+)Tpo(-/-) mice, although thrombocytosis was reduced compared with JAK2V617F(+) mi

215 Thrombocytosis was significantly associated with advance

216 Extreme thrombocytosis was significantly associated with infused

217 ce, which exhibit iron deficiency anemia and thrombocytosis, we observed a Mk bias, decreased labile

218 To augment current diagnostic studies for thrombocytosis, we retrospectively evaluated clinical re

219 Leukocytosis and thrombocytosis were also detected in infected gerbils, i

220 nd relative risks for cancer associated with thrombocytosis were estimated for all cancers and for ca

221 ted genes in polycythemia vera and essential thrombocytosis were involved predominantly in cell signa

222 mical inhibitors could promote a paradoxical thrombocytosis when used at suboptimal doses.

223 umor and host tissue leads to paraneoplastic thrombocytosis, which fuels tumor growth.

224 a transplantable ET-like disease with marked thrombocytosis, which is associated with increased and m

225 mice displayed profound megakaryocytosis and thrombocytosis with a remarkable expansion of megakaryoc

226 DSS colitis in WT mice was associated with thrombocytosis with an elevated number of both mature an

227 Both murine models exhibited thrombocytosis with increased megakaryocytes and megakar

228 routine blood work in June 2011 to have mild thrombocytosis, with a platelet count of 405,000.

229 lungs during stimulated as well as reactive thrombocytosis without precluding observations that some